Rapport Therapeutics (RAPP) grants COO 132,000 stock options

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. reported that Chief Operating Officer Cheryl Gault received a stock option grant for 132,000 shares of common stock on February 2, 2026, with an exercise price of $27.75 per share and expiration on February 2, 2036.

The option vests in forty-eight equal monthly installments starting after January 1, 2026, conditioned on her continued service with the company. Following this grant, she beneficially owns 132,000 derivative securities directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Gault Cheryl

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	132,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 132,000 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gault Cheryl

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$27.75	02/02/2026		A		132,000		(1)	02/02/2036	Common Stock	132,000	$0	132,000	D

Explanation of Responses:

1. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following January 1, 2026, subject to the Reporting Person's continued service on each such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rapport Therapeutics (RAPP) disclose in this Form 4 filing?

Rapport Therapeutics disclosed a stock option grant to its Chief Operating Officer, Cheryl Gault. She received options for 132,000 shares of common stock, documenting an equity-based compensation award and her updated beneficial ownership position in the company’s derivative securities.

How many stock options did Rapport Therapeutics COO Cheryl Gault receive?

Cheryl Gault received stock options for 132,000 shares of Rapport Therapeutics common stock. These options were granted on February 2, 2026, and represent her entire reported beneficial ownership of derivative securities following this transaction, held directly in her name.

What is the exercise price and expiration date of the RAPP stock options?

The stock options granted to Cheryl Gault have an exercise price of $27.75 per share. They are scheduled to expire on February 2, 2036, providing a long-term incentive window during which she may choose to exercise the options, subject to vesting conditions.

How do the Rapport Therapeutics options granted to the COO vest over time?

The options vest in forty-eight equal monthly installments after January 1, 2026. Each monthly vesting is contingent on Cheryl Gault’s continued service with Rapport Therapeutics on the applicable vesting date, gradually increasing the portion of options that become exercisable.

Is the COO’s ownership in Rapport Therapeutics direct or indirect in this filing?

The Form 4 shows that the 132,000 stock options are held with direct ownership by Cheryl Gault. The filing does not reference any intermediary entities or indirect ownership structures for this grant, and no separate nature of indirect beneficial ownership is indicated.